Eric J. Sorscher

Internal Medicine

619 19th St S
Birmingham, AL 35233

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 93 publications

Elexacaftor-Tezacaftor-Ivacaftor for Individuals with Residual CFTR Activity: An Open-Label, Nonrandomized Clinical Trial.

Elexacaftor-Tezacaftor-Ivacaftor for Individuals with Residual CFTR Activity: An Open-Label, Nonrandomized Clinical Trial.

Journal: Annals of the American Thoracic Society

Published: March 06, 2026

Elexacaftor-tezacaftor-ivacaftor for individuals with residual CFTR activity: an open-label, nonrandomized clinical trial.

Elexacaftor-tezacaftor-ivacaftor for individuals with residual CFTR activity: an open-label, nonrandomized clinical trial.

Journal: Annals of the American Thoracic Society

Published: March 06, 2026

Barriers to the Pharmacologic Rescue of W1282X CFTR.

Barriers to the Pharmacologic Rescue of W1282X CFTR.

Journal: Biochemistry

Published: December 12, 2025

Generation of Region-specific Airway Basal Stem Cells from Human Pluripotent Stem Cells via Regulation of BMP-NOGGIN Axis.

Generation of Region-specific Airway Basal Stem Cells from Human Pluripotent Stem Cells via Regulation of BMP-NOGGIN Axis.

Journal: bioRxiv : the preprint server for biology

Published: November 19, 2025

Reconstitution of CFTR ubiquitination identifies lysine-420 as a regulator of cell surface residence and current.

Reconstitution of CFTR ubiquitination identifies lysine-420 as a regulator of cell surface residence and current.

Journal: Biochemistry and biophysics reports

Published: October 10, 2025

Transformative Research in Cystic Fibrosis.

Transformative Research in Cystic Fibrosis.

Journal: The New England journal of medicine

Published: September 11, 2025

Large variations in total and allele-specific transcript expression in a disease mutation-independent manner.

Large variations in total and allele-specific transcript expression in a disease mutation-independent manner.

Journal: Scientific reports

Published: August 03, 2025

A novel drug series optimized to address cystic fibrosis and other CFTR deficiency diseases of human airways.

A novel drug series optimized to address cystic fibrosis and other CFTR deficiency diseases of human airways.

Journal: npj drug discovery

Published: May 25, 2025

Broadening activity of checkpoint blockade agents by intratumoral nucleoside cleavage.

Broadening activity of checkpoint blockade agents by intratumoral nucleoside cleavage.

Journal: JCI insight

Published: April 15, 2025

Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol.

Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocol.

Journal: PloS one

Published: December 03, 2024

Nucleic acid-based drugs for patients with solid tumours.

Nucleic acid-based drugs for patients with solid tumours.

Journal: Nature reviews. Clinical oncology

Published: March 18, 2024

Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial.

Evaluation of elexacaftor-tezacaftor-ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial.

Journal: The Lancet. Respiratory medicine

Published: February 29, 2024

Showing 1-12 of 93

Last Updated: 09/26/2026